CD274 and neoplasm: Using a different combinatorial approach, Zhang et al. engineered two different types of NPs: one loaded with an anti-PD-L1 small molecule inhibitor (BMS-1 NP), and another loaded with docetaxel (DTX) chemotherapy and VTX-2337, a toll-like receptor 8 agonist capable of polarizing M2 macrophages into the M1 anti-tumor phenotype (DTX@VTX NP).